Detalles de la búsqueda
1.
Accuracy of the Enhanced Liver Fibrosis Test in Patients With Type 2 Diabetes Mellitus and Its Clinical Implications.
Clin Gastroenterol Hepatol
; 22(4): 789-797.e8, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38048934
2.
Comparison of prognostic impact of atezolizumab plus bevacizumab versus lenvatinib in patients with intermediate-stage hepatocellular carcinoma.
Liver Int
; 44(1): 113-124, 2024 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37789669
3.
Comparative analysis of the therapeutic outcomes of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma patients aged 80 years and older: Multicenter study.
Hepatol Res
; 54(4): 382-391, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-37983642
4.
Comparison of six hepatocellular carcinoma prediction models in Japanese patients after sustained virologic response undergoing rigorous surveillance for hepatocellular carcinoma.
J Gastroenterol Hepatol
; 39(5): 949-954, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38291715
5.
Mortality in patients with chronic hepatitis B treated with tenofovir or entecavir: A multinational study.
J Gastroenterol Hepatol
; 2024 Mar 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-38480009
6.
Poor Diagnostic Efficacy of Noninvasive Tests for Advanced Fibrosis in Obese or Younger Than 60 Diabetic NAFLD patients.
Clin Gastroenterol Hepatol
; 21(4): 1013-1022.e6, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35654298
7.
Nutritional Status Is Associated with Prognosis in Patients with Advanced Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab.
Oncology
; 101(4): 270-282, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36455517
8.
Lenvatinib as Second-Line Treatment after Atezolizumab plus Bevacizumab for Unresectable Hepatocellular Carcinoma: Clinical Results Show Importance of Hepatic Reserve Function.
Oncology
; 101(10): 624-633, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37307798
9.
Comparison between Atezolizumab Plus Bevacizumab and Lenvatinib for Hepatocellular Carcinoma in Patients with Child-Pugh Class B in Real-World Clinical Settings.
Oncology
; 101(9): 542-552, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37552968
10.
Diagnostic accuracy of enhanced liver fibrosis test for nonalcoholic steatohepatitis-related fibrosis: Multicenter study.
Hepatol Res
; 53(4): 312-321, 2023 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-36524984
11.
Validation of the utility of Agile scores to identify advanced fibrosis and cirrhosis in Japanese patients with nonalcoholic fatty liver disease.
Hepatol Res
; 53(6): 489-496, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-36807720
12.
Association of proton pump inhibitor and antibiotic use with the clinical outcomes of hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: A multicenter analysis.
Hepatol Res
; 53(8): 737-748, 2023 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-37020416
13.
Geriatric nutritional risk index as an easy-to-use assessment tool for nutritional status in hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
Hepatol Res
; 53(10): 1031-1042, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37306040
14.
Impact of first-line systemic therapy with atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.
J Gastroenterol Hepatol
; 38(8): 1389-1397, 2023 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-37231943
15.
Treatment and Renal Outcomes Up to 96 Weeks After Tenofovir Alafenamide Switch From Tenofovir Disoproxil Fumarate in Routine Practice.
Hepatology
; 74(2): 656-666, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-33706421
16.
Clinical Predictor of Urinary Protein as Adverse Event Associated with Atezolizumab plus Bevacizumab Treatment for Unresectable Hepatocellular Carcinoma.
Oncology
; 100(12): 645-654, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36103846
17.
The Risk of Cirrhosis and Its Complications Based on PNPLA3 rs738409 G Allele Frequency.
Dig Dis
; 40(5): 625-634, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-34808618
18.
Association of early bevacizumab interruption with efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: A landmark analysis.
Hepatol Res
; 52(5): 462-470, 2022 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-35080087
19.
Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC-B stage patients classified as beyond up to seven criteria - Multicenter analysis.
Hepatol Res
; 52(3): 308-316, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-34799975
20.
Time-course changes in liver functional reserve after successful sofosbuvir/velpatasvir treatment in patients with decompensated cirrhosis.
Hepatol Res
; 52(3): 235-246, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-34861090